Since 1930, there have been fewer than 1000 cases of the disease reported around the world.
A new case study details a 65-year-old patient diagnosed with Erdheim-Chester disease (ECD), a rare histiocytic neoplasm that uncommonly presented with gastroenterological manifestations.
The clinical presentations of ECD vary. While some patients are asymptomatic and the condition is incidentally detected via imaging, others experience multiorgan dysfunction and a rapidly progressive disease.
The condition was first described in 1930 and since then, fewer than 1000 cases have been reported worldwide, researchers explained. Although ECD typically affects the skeletal system, over half of patients also have extraskeletal involvement. It has no known cure and prognosis varies based on treatment response and disease site.
Upon first presentation, the current patient had hematuria and abdominal pain. The male patient underwent a computed tomography scan that revealed a retroperitoneal mass. He also experienced night sweats, nausea, and intermittent non-bloody diarrhea.
Medical history queries revealed coronary artery disease with previous myocardial infarction, impaired fasting glucose, and hypertension. “A CT-guided biopsy of the mass showed dense fibroadipose tissue with predominant lymphocytes and plasma cells,” authors wrote.
After being seen by an oncologist and undergoing a nondiagnostic bone marrow biopsy, the patient was referred to the current gastroenterology clinic for evaluation of his unexplained weight loss, nausea and other symptoms.
Images carried out at the center revealed “retroperitoneal fibrosis surrounding both kidneys, renal vessels, left ureter, proximal right ureter, portions of the aorta, common iliac arteries, and the left internal and external iliac arteries without any evidence of vascular obstruction or hydronephrosis.”
The patient then underwent a laparoscopic retroperitoneal biopsy, which showed “fibroadipose tissue involved by a subtle histiocytic infiltrate in a background of marked fibrosis, scattered lymphocytes, and plasma cells,” authors wrote.
Following the detection of the BRAF V600E mutation within the histiocytes, the patient was diagnosed with ECD.
Most patients with ECD are diagnosed within the fourth and seventh decade of life, and most cases occur in males. Clinical manifestations of ECD include diabetes insipidus, mediastinal infiltration, orbital masses, and cardiac involvement. However, “involvement of liver, pancreas, and gastrointestinal tract is extremely rare,” authors said. Gastrointestinal symptoms, though uncommon, can include vomiting, abdominal pain and nausea.
Because the current patient had such a nonspecific presentation, authors noted there was a broad range of differential diagnoses for retroperitoneal masses, including neoplastic retroperitoneal masses like lymphoma. It could have also been liposarcoma, leiomyosarcoma, neurogenic tumors, or germ-cell tumors or even benign etiologies like precious radiation therapy or IgG4-related disease (IgG4-RD).
Thanks to the retroperitoneal involvement and tissue IgG4 staining, IgG4-RD was initially considered, though this condition is typically associated with a raised serum IgG4, which was absent in the patient.
Treatment is recommended for all symptomatic patients with ECD, researchers wrote, and targeted therapy is the preferred modality.
“Vemurafenib selectively inhibits the kinase domain of mutant BRAF and is used as first-line therapy for individuals with BRAF V600E ECD. MEK inhibitors may be considered for ECD patients without BRAF V600E,” they said.
The patient was started on vemurafenib. A positron emission tomography scan was carried out three months later and showed radiologic improvement. On his subsequent follow-up he was diagnosed with concomitant chronic myelomonocytic leukemia, was initiated on cobimetinib, and has been doing well for 2 years.
“Although uncommon, physicians should consider the possibility of ECD when evaluating patients who have persistent unexplained gastrointestinal complaints and retroperitoneal perinephric mass-like infiltration on cross-sectional imaging,” authors concluded.
Reference
Chatterjee A, de la Fuente J, Rech K, Takahashi N, and Majumder S. A rare case of abdominal pain: Edrheim-chester disease. ACG Case Rep J. Published online June 2023. doi:10.14309/crj.0000000000001049
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More